Results 11 to 20 of about 5,406 (200)

In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates

Pharmaceutics, 2022
Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik, Przemysław Koźmiński, Joanna Matalińska, Piotr F. J. Lipiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +2 more sources

Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs [PDF]

Virulence, 2020
With the rapid increase in the frequency of azole-resistant species, combination therapy appears to be a promising tool to augment the antifungal activity of azole drugs against resistant Candida species.
Hassan E. Eldesouky, Nadia A. Lanman, Tony R. Hazbun, Mohamed N. Seleem   +3 more
doaj   +2 more sources

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush [PDF]

Case Reports in Oncology, 2019
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer ...
Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe   +12 more
doaj   +2 more sources

Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis

Acta Dermato-Venereologica, 2017
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disorder that may worsen due to stress and anxiety. Tachykinins have been suggested to be involved in the inflammation in AD, as well as pruritus.
Louise Lönndahl, Mikael Holst, Maria Bradley, Hassan Killasli, Johan Heilborn, Martin A. Hall, Elvar Theodorsson, Jadwiga Holmberg, Klas Nordlind   +8 more
doaj   +2 more sources

Enhanced anti-angiogenic effects of aprepitant-loaded nanoparticles in human umbilical vein endothelial cells

Scientific Reports
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents.
Elif Kaya-Tilki, Ahmet Alper Öztürk, Selin Engür-Öztürk, Miriş Dikmen   +3 more
doaj   +2 more sources

Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant

Case Reports in Oncology, 2014
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation.
Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert   +6 more
doaj   +2 more sources

Aprepitant is a novel, selective activator of the K2P channel TRAAK [PDF]

, 2021
TRAAK (KCNK4, K2P4.1) is a mechanosensitive two-pore domain potassium (K2P) channel. Due to its expression within sensory neurons and genetic link to neuropathic pain it represents a promising potential target for novel analgesics.
Veale, E L, Vaitone, E., Mathie, Alistair, McCoull, D, Wright, P.D., Byrom, L, Avkiran, T., Jerman, J., Large, J.M., Vaitone, E, Large, J M, Walsh, Yvonne, Wright, P D, McCoull, D., Byrom, L., Gaffey, F, Avkiran, T, Veale, Emma L., Gaffey, F., Walsh, Y, Jerman, J, Walsh, Y., Veall, E.L., Mathie, A., E. Vaitone, F. Gaffey, Y. Walsh, L. Byrom, E.L. Veale, A. Mathie, J. Jerman, T. Avkiran, J.M. Large, D. McCoull, P.D. Wright   +34 more
core   +1 more source

From Real World Data to Real Impact: A Co-Medication Framework for Lung Cancer to Advance DDI Assessment and Patient-Centric Drug Development. [PDF]

Clin Transl Sci
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Biju M, Choi H, Madari S, Carlisle A, Sharma A, Kunz C, Huang F.   +6 more
europepmc   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain

Frontiers in Pharmacology, 2022
Substance P contributes to the pathogenesis of pain by acting on NK-1R, specialized sensory neurons that detect noxious stimuli. Aprepitant, an antagonist of NK-1R, is widely used to treat chemotherapy-induced nausea and vomiting.
Yang Yang, Wei Zhou, Xiuqi Xu, Xianxiu Ge, Fei Wang, Guang-Qin Zhang, Lin Miao, Xueting Deng   +7 more
doaj   +1 more source